Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
Neeta Somaiah, Anthony P. Conley, Edwin R. Parra, Heather Lin, Behrang Amini, Luisa M. Solis Soto, Ruth Salazar, Carmélia Maria Noia Barreto, Honglei Chen, Swati Gite, Cara Haymaker, Elise F. Nassif, Chantale Bernatchez, Akash Mitra, J. Andrew Livingston, Vinod Ravi, Dejka M. Araujo, Robert S. Benjamin, Shreyaskumar Patel, Maria A. Zarzour, Sharjeel Sabir, Alexander J. Lazar, Wei‐Lien Wang, Najat C. Daw, Xiao Zhou, Christina L. Roland, Zachary A. Cooper, Jaime Rodriguez‐Canales, P. Andrew Futreal, Jean‐Charles Soria, Ignacio I. Wistuba, Patrick Hwu
Topics & Concepts
DurvalumabMedicineTremelimumabSarcomaInternal medicinePopulationSoft tissue sarcomaOncologyAdverse effectClinical endpointSurgeryCancerClinical trialPathologyPembrolizumabIpilimumabImmunotherapyEnvironmental healthSarcoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersMusculoskeletal synovial abnormalities and treatments